VALNEVA 
2013 financial calendar
VIVALIS SHARES transferred to compartment B of NYSE Euronext
Nantes (France) - 11 janvier 2010 - VIVALIS (NYSE EuroneNantes, Lyon (France) - 15 January 2013- VIVALIS (NYSE Euronext), a biopharmaceutical company, today announces its schedule for the publication of financial information for 2013.
On December 16, 2012, VIVALIS and INTERCELL announced a proposed merger of equals with the objective to create VALNEVA, a leading European biotechnology company in vaccines and antibodies. This merger will create an integrated company with a greater scale and diversification, strengthened financial profile and complementary talent and capabilities.
| Event | Date * ** |
| 2012 fourth-quarter and annual revenues | Thursday, 14 February 2013 |
| Shareholders' meeting on VIVALIS-INTERCELL Merger to form VALNEVA S.E. | Early March 2013 |
| 2012 annual results | Tuesday, 26 March 2013 |
| 2013 first-quarter revenues | Thursday, 25 April 2013 |
| Annual general meeting | Wednesday, 19 June 2013 |
* Subject to modification.
** Press releases are published after market closes
Upon completion of the merger, if approved, a new financial calendar will be circulated for the financial publications of VALNEVA S.E.
In addition, NYSE Euronext has transfered VIVALIS shares from compartment C of the Euronext to compartment B of the Euronext. This transfer will be effective beginning 17 January 2013.
About VIVALIS (www.vivalis.com:
http://www.vivalis.com)
Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the biotechnology and pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs. Vivalis' expertise and intellectual property are leveraged in two main areas:
- EB66® Cell Line
Vivalis offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLPs and recombinant proteins, including monoclonal antibodies. Clinical trials of EB66® produced vaccines are currently on-going in the USA and Japan and in 2012 a vaccine produced in EB66® cells received market approval in Japan for use in animal health. Through these programs, Vivalis receives an upfront payment, clinical stage milestone payments along with royalties on licensees' net sales.
- VIVA|Screen(TM) Human Antibody Discovery Platform
Customized solutions for the discovery, development and production of rare, fully human monoclonal antibodies are offered by Vivalis. Through these programs, Vivalis receives payments associated with the funding of discovery research, an upfront payment, clinical stage milestone payments along with royalties on net sales of licensed antibodies that are commercially developed from the use of the platform.
Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Group Grimaud (approx. 1,700 employees), one of the worldwide leaders in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in biopharmaceutical industry, including Sanofi Pasteur, GlaxoSmithKline Biologicals, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE based in Toyama.
| VIVALIS Listed on Euronext Paris - Compartment C of NYSE Euronext Reuters: VLS.PA - Bloomberg: VLS FP Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes |
This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's Document de Référence, changes in economic conditions, the financial markets or the markets in which the company operates.
Contacts
| VIVALIS | NewCap |
| Franck Grimaud, CEO | Financial communications agency |
| Email: investors@vivalis.com | Axelle Vuillermet / Pierre Laurent |
| Tel.: +33 (0) 1 44 71 94 93 | |
| Email: vivalis@newcap.fr |
http://hugin.info/143334/R/1670533/542869.pdf
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: VIVALIS via Thomson Reuters ONE
